CDK, the leading automotive retail software provider, today announced the extension of its agreement with Sonic Automotive, ...

The contract extension with Sonic is a win for market leader CDK, which faced challenges over the summer after two ...

The news reinforces CDK's reputation in the DMS business and, presumably, will help the company land more extensions and new ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

It hasn’t been the best of years for CDK Global, but it got some good news Monday. Sonic Automotive, one of the nation’s ...

Roche is spending $850 million upfront to buy Regor Pharmaceuticals’ suite of next-generation CDK inhibitors as it doubles ...

Sino-American biotech Regor Pharmaceuticals has entered into a definitive purchase agreement whereby Swiss pharma major Roche ...

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash payment ...

Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will ...

Regor Pharmaceuticals (USA) said it is selling a portfolio of CDK inhibitors used to treat breast cancer to Roche Holding unit Genentech for an upfront payment of $850 million.

The dollar index Monday rose by +0.45%. The dollar Monday recovered from overnight losses and rallied moderately on hawkish comments from Fed Governor Bowman that reduced chances ...